Pharmacoflash 15 : Neurology

16:15 • 181 • Use of Therapeutic Drug Monitoring of Antipsychotics in Routine Clinical Practice: A Retrospective Study from a French University Hospital > E-J. Edouard-Jules Laforgue 16:21 • 339 • Impact of early CYP2C19 genotyping on escitalopram treatment failure > E. Espen MOLDEN 16:27 • 678 • Therapeutic Drug Monitoring of Brivaracetam: Real-World Exposure Variability and Clinical Implications > S. Sara Baldelli 16:33 • 414 • Reprocessing high-resolution mass spectra from TDM samples of escitalopram reveals comedication with proton pump inhibitors causing significant phenoconversion of escitalopram metabolism > B. Birgit M. Wollmann 16:39 • 604 • Integration of therapeutic drug monitoring (TDM) and pharmacogenetic testing within a structured personalized pharmacology platform (MONITOR): Application to treatment-resistant depression in an older patient > E. Emuri Abe 16:45 • 692 • Association Between Risperidone Plasma Concentrations, D2 Receptor occupancy and Treatment Response: A Systematic Review, Meta-analysis and Individual Participant Data Meta-analysis > M. Maxime Moiny 16:51 • 703 • From Identifiability Screening to Meta-Model Development: A Simulation Study of Clozapine–Norclozapine Pharmacokinetics > S. Stanislas Maisonneuve